Search Results - "immunogenicity"

Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children by Tawee Chotpitayasunondh, Piyarat Suntarattiwong, Sutee Yoksan

Connect to this object online.

Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial. by John Tyler Sandberg, Marie Löfling, Renata Varnaitė, Johanna Emgård, Nabil Al-Tawil, Lars Lindquist, Sara Gredmark-Russ, Jonas Klingström, Karin Loré, Kim Blom, Hans-Gustaf Ljunggren

Connect to this object online.

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study by Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza, Philipp Oster

Connect to this object online.

Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers by Dipesh Tamrakar, Pranodan Poudel, Pragya Thapa, Srijana Singh, Amit Khadgi, Sameera Thapa, Rajendra Tamrakar, Anmol Shrestha, Surendra Madhup, Ganesh Kumar Rai, Birendra Prasad Gupta, Tarun Saluja, Sushant Sahastrabuddhe, Rajeev Shrestha

Connect to this object online.

Safety, immunogenicity of lyophilized purified vero cell cultured rabies vaccine administered in Zagreb and Essen regimen in post-exposure subjects: A post-marketing, parallel control clinical trial by Lei Zhang, Shichun Huang, Li Cai, Zhenggang Zhu, Jian Chen, Sha Lu, Zerong Zhu, Man Zhang, Yuan Fang, Quan Hu

Connect to this object online.

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents by Timo Vesikari, Jerzy Brzostek, Anitta Ahonen, Marita Paassilta, Ewa Majda-Stanislawska, Leszek Szenborn, Miia Virta, Robert Clifford, Teresa Jackowska, Murray Kimmel, Ilaria Bindi, Pavitra Keshavan, Paola Pedotti, Daniela Toneatto

Connect to this object online.

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K Ariën, Maria E Goossens

Connect to this object online.

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses by Patrick DMC Katoto, Mireille AM Kakubu, Jacques L. Tamuzi, Amanda S. Brand, Adaeze Ayuk, Liliane N. Byamungu, Charles S. Wiysonge, Glenda Gray

Connect to this object online.

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial by Zhao-Jun Mo, Zhao-Feng Bi, Wei Sheng, Qi Chen, Teng Huang, Ming-Qiang Li, Xue-Lian Cui, Ya-Hui Wangjiang, Bi-Zhen Lin, Feng-Zhu Zheng, Guang Sun, Ya-Fei Li, Ya Zheng, Si-Jie Zhuang, Ying-Ying Su, Hui-Rong Pan, Shou-Jie Huang, Ting Wu, Jun Zhang, Ning-Shao Xia

Connect to this object online.

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial by Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen, Phong M. Tran, Thuan D. Nghiem, Tien V. Tran, Tien G. Nguyen, Tuynh Q. Tran, Linh T. Nguyen, Anh T. Do, Dung D. Nguyen, Son A. Ho, Viet T. Nguyen, Dung T. Pham, Hieu B. Tran, Son T. Vu, Su X. Hoang, Trung M. Do, Xuan T. Nguyen, Giang Q. Le, Ton Tran, Thang M. Cao, Huy M. Dao, Thao T.T. Nguyen, Uyen Y Doan, Vy T.T. Le, Linh P. Tran, Ngoc M. Nguyen, Ngoc T. Nguyen, Hang T.T. Pham, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Nguyen, Vinh T. Tran, Mai T.N. Tran, Truc T.T. Nguyen, Phat T. Ha, Hieu T. Huynh, Khanh D. Nguyen, Ung T. Thuan, Chung C. Doan, Si M. Do

Connect to this object online.

Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called "Karanahan" Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model by Vera Ruzanova, Vera Ruzanova, Anastasia Proskurina, Yaroslav Efremov, Yaroslav Efremov, Svetlana Kirikovich, Genrikh Ritter, Evgenii Levites, Evgenia Dolgova, Ekaterina Potter, Oksana Babaeva, Sergey Sidorov, Sergey Sidorov, Oleg Taranov, Alexandr Ostanin, Elena Chernykh, Sergey Bogachev

Connect to this object online.

Safety and immunogenicity of an adjuvanted Escherichia coli adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 study by Gary R. Eldridge, Heidi Hughey, Lois Rosenberger, Steven M. Martin, Andrew Marc Shapiro, Elizabeth D'Antonio, Kent G. Krejci, Neal Shore, James Peterson, Andrea S. Lukes, Courtney M. Starks

Connect to this object online.

Preparation of Proper Immunogen by Cloning and Stable Expression of cDNA coding for Human Hematopoietic Stem Cell Marker CD34 in NIH-3T3 Mouse Fibroblast Cell Line by Farzaneh Shafaghat, Hajar Abbasi-Kenarsari, Jafar Majidi, Ali Akbar Movassaghpour, Dariush Shanehbandi, Tohid Kazemi

Connect to this object online.

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial by Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, Leo Heyndrickx, Johan Michiels, Elisabeth Willems, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, Véronique Olislagers, Alexandra Waegemans, Mathieu Verbrugghe, Marie-Noëlle Schmickler, Steven Van Gucht, Katelijne Dierick, Arnaud Marchant, Isabelle Desombere, Kevin K. Ariën, Maria E. Goossens

Connect to this object online.

Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study by Paul Gillard, Tsuyoshi Tamura, Haruo Kuroki, Yoshiyuki Morikawa, Leentje Moerman, Jose Parra, Yurina Kitamura, Kazuko Mihara, Arisa Okamasa

Connect to this object online.

Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China by Jialei Hu, Hongguang Li, Kai Chu, Qi Liang, Jingxin Li, Li Luo, Yuemei Hu, Fanyue Meng, Fengcai Zhu

Connect to this object online.

Immunogenicity and immune persistence of Zagreb 2-1-1 regimen of rabies vaccine in Chinese healthy individuals: A randomized, parallel-controlled of homologous vaccine with different immune procedure study by Li Li, Jingyi Xu, Jiao Zhang, Fang Wang, Jianlin Cai, Liqing Yang, Zhenggang Zhu, Yunhua Bai, Bin Jia, Jianxin Ma, Nianmin Shi, Shuping Li

Connect to this object online.

Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial by Jingjun Qiu, Yunkai Yang, Lirong Huang, Ling Wang, Zhiwei Jiang, Jian Gong, Wei Wang, Hongyan Wang, Shaohong Guo, Chanjuan Li, Shuyuan Wei, Zhaojun Mo, Jielai Xia

Connect to this object online.

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. by Vianney Tricou, Brandon Essink, John E Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, Derek Wallace

Connect to this object online.

A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report by Bernie Endyarni Medise, Soedjatmiko Soedjatmiko, Hartono Gunardi, Rini Sekartini, Hindra Irawan Satari, Sri Rezeki Hadinegoro, Angga Wirahmadi, Mita Puspita, Rini Mulia Sari, Jae Seung Yang, Arijit Sil, Sushant Sahastrabuddhe, Novilia Sjafri Bachtiar

Connect to this object online.